Medixon Indications/Uses

Treatment of Abnormal Adrenocorticoid Function: Primary acute and chronic adrenocortical insufficiency. Hydrocortisone and cortisone are preferred as adjunctive replacement therapy because of their significant mineralocorticoid activities. Replacement of sodium and fluids is required. In some patients, additional mineralocorticoid replacement may also be necessary.
Secondary Adrenocorticoid Insufficiency: Glucocorticoid replacement is usually sufficient, a mineralocorticoid is not always required.
Allergic Disorders: Drug allergy, anaphylactic or anaphylactoid reaction (adjunctive therapy). Use of glucocorticoids is generally reserved for prolonged reactions (those not responding to other forms of treatment within 1 hr) or situations in which there is a significant risk of relapse. Angioedema (adjunctive therapy); acute noninfectious laryngeal edema; seasonal or perennial allergic rhinitis (chronic or acute); serum sickness; urticarial transfusion reaction.
Collagen Disorders: During an acute exacerbation or as maintenance therapy in the cases of: Acute rheumatic (or nonrheumatic) carditis. Systemic dermatomyositis (polymyositis). Glucocorticoids may be the treatment of choice in children with this condition. Systemic lupus erythematosus; 'giant-cell' arthritis (temporary); complicated bound tissue disease; polyarthritis nodosa; polychondritis relapse; rheumatoid polymyalgia; vasculitis.
Dermatologic Disorders: Atopic, contact or exfoliative dermatitis; bullous dermatitis herpetiformis; moderate seborrheic dermatitis; moderate inflammatory dermatitis; moderate erythema multiforme (Stevens-Johnson syndrome); mycosis fungoides; pemphigus; moderate psoriasis; pemphigoid; localized cutaneous sarcoid.
GI Disorders: Treatment of the inflammatory bowel disease, including ulcerative colitis, regional enteritis (Crohn's disease), moderate cellac disease. Oral or parenteral administration is indicated when systemic therapy is required during a clinical period of the disease; long-term use is not recommended.
Hematologic Disorders: Acquired hemolytic anemia (autoimmune), congenital (erythroid) hypoplastic anemia, red blood cell anemia (erythroblastopenia), secondary thrombocytopenia (in adults), idiopathic thrombocytopenia purpura in adults (oral or IV administration only, IM administration is contraindicated), hemolysis.
Hepatic Disease: Alcoholic hepatitis with encephalopathy, chronic active hepatitis, nonalcoholic hepatitis in women, subacute hepatic necrosis.
Hypercalcemia associated with neoplasms (or sarcoidosis).
Nonrheumatoid Inflammation: During an acute episode or exacerbation of the following disorders (local injection is preferred when only a few joints or areas are affected): Acute and subacute bursitis, epicondylitis, acute nonspecific tenosynovitis.
Neoplastic Disease (Adjunctive Therapy): In conjunction with appropriate specific antineoplastic disease therapy for the palliative management of the following neoplastic diseases and related problems: Acute leukemia or chronic lymphocytic, Hodgkin's or non-Hodgkin's lymphomas, breast and prostatic cancer, fever caused by severe cancer, multiple myeloma.
Nephrotic Syndrome: To induce diuresis or to reduce proteinuria symptoms in idiopathic nephrotic syndrome; long-term therapy may be required to prevent frequent relapses.
Neurologic Disease: Tuberculosis meningitis (adjunctive therapy), concurrent administration with appropriate antituberculous chemotherapy in patients with subarachnoid block. Treatment of acute exacerbations in multiple sclerosis.
Neurotrauma: Spinal cord injury.
Ophthalmic Disorders: Treatment of chronic or acute allergic and inflammatory ophthalmic conditions eg, chorioretinitis, choroiditis posterior diffusion, allergic conjunctivitis (controlled diffuse posterior choroiditis), herpes zoster, iridocyclitis, keratitis not associated with herpes simplex or fungal infection, optic neuritis, sympathetic ophthalmia, diffuse posterior uveitis.
Pericarditis: Used to eliminate inflammation and fever. Nasal polyps.
Treatment and prophylaxis of respiratory diseases.
Prophylaxis: Given before or during heart surgery if patient has a preexisting pulmonary disorder, and given before, during and after oral, facial or neck surgery to prevent edema that may inhibit the airway. Treatment of bronchial asthma; berylliosis; Loeffler syndrome (eosinophilic pneumonitis or hypereosinophilic syndrome); aspiration pneumonia; symptomatic sarcoidosis; fulminating or disseminated pulmonary tuberculosis (treatment adjunct) when used concurrently with appropriate tuberculosis chemotherapy; acute and chronic asthmatic bronchitis; noncardiogenic pulmonary edema (caused by protamine sensitivity, treatment should be administered IV/IM injection); Pneumocystis carinii pneumonia associated with AIDS (treatment adjunct), in patients infected with HIV virus with Pneumocystis pneumonia; chronic obstructive pulmonary disease (not controlled with theophylline and β-adrenergic agonist; status asthmaticus should be given by IV/IM injection.
Airway-obstructing hemangioma; medication in children should be administered by IV/IM injection.
Rheumatic Disorders: Local injections should be applied if only few joints or areas are involved; adjunctive therapy during an acute episode or exacerbation of rheumatic disorders eg, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis [(including arthritis in children), for patients that cannot be treated with aspirin, steroidal anti-inflammatory drugs, rest and physical therapy]; acute gouty arthritis; post-traumatic osteoarthritis, osteoarthritis synovitis, acute calcium pyrophosphate deposition disease (pseudo-gout chondrocalcinosis, synovitis caused by crystals); rheumatica polymyalgia; Reiter's disease.
Shock therapy caused by adrenocortical insufficiency; nonsuppurative thyroiditis.
Prophylaxis and treatment in organ transplant rejection administered concurrently with other immunosuppressants eg, azathioprine or cyclosporine; trichinosis treatment.